National Health (Listed drugs on F1 or F2) Amendment Determination 2012 (No. 5) (No. PB 53 of 2012)

Link to law: https://www.comlaw.gov.au/Details/F2012L01621

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
National Health (Listed drugs on F1 or F2) Amendment Determination 2012 (No. 5)
Instrument number PB 53 of 2012
National Health Act 1953
I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the
Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.
Dated              27            July   2012
 
 
 
 
 
 
 
 
 
ADRIANA PLATONA
 
Assistant Secretary
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health and Ageing
 
 
Part 1         Preliminary
1              Name of Determination
         (1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2012 (No. 5).
         (2)   This Determination may also be cited as PB 53 of 2012.
2              Commencement
                This Determination commences on 1 August 2012.
3              Amendment of National Health (Listed drugs on F1 or F2) Determination 2010
                Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).
Schedule 1             Amendments
 
(Section 3)
 
[1]     Schedule 1, after item dealing with Busulfan
 
Insert
 
Cabazitaxel 
 
[2]     Schedule 1, after item dealing with Hydromorphone
 
Omit
 
Hydroxychloroquine 
 
[3]     Schedule 1, after item dealing with Ibuprofen
 
Insert
 
Icatibant 
 
[4]     Schedule 1, after item dealing with Lacosamide
 
Omit
 
Lamivudine 
 
[5]     Schedule 1, after item dealing with Lapatinib
 
Omit
 
Latanoprost 
 
[6]     Schedule 1, after item dealing with Losartan
 
Insert
 
Mannitol 
 
[7]     Schedule 1, after item dealing with Posaconazole
 
Omit
 
Pramipexole 
 
[8]     Schedule 1, after item dealing with Ranibizumab
 
Insert
 
Rasagiline 
 
[9]     Schedule 1, after item dealing with Tiaprofenic acid
 
Insert
 
Ticagrelor 
 
[10]   Schedule 1, after item dealing with Tocilizumab
 
Omit
 
Topotecan 
 
[11]   Schedule 2, after item dealing with Hydroxocobalamin
 
Insert
 
Hydroxychloroquine 
 
[12]   Schedule 2, after item dealing with Lactulose
 
Insert
 
Lamivudine 
 
[13]   Schedule 2, after item dealing with Lansoprazole
 
Insert
 
Latanoprost
Latanoprost with timolol 
 
[14]   Schedule 2, after item dealing with Potassium chloride with potassium bicarbonate
 
Insert
 
Pramipexole
 
[15]   Schedule 2, after item dealing with Topiramate
 
Insert
 
Topotecan
 
 
Note
1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.frli.gov.au.